Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02504580 · ClinicalTrials.gov registry record · Phase 2

Pilot Herniorrhaphy Study for Postoperative Analgesia

A Phase 2 study of Postoperative Pain, sponsored by Heron Therapeutics.

Completed
Registry status
Phase 2
Development phase
463
Enrollment target
3
Study locations

NCT02504580 is a Phase 2 study of Postoperative Pain that has completed, run by Heron Therapeutics. The registered enrollment target is 463 participants, above the 224-participant average among 63 other Postoperative Pain trials with a reported enrollment target (107% higher). The trial reports 3 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02504580, a Phase 2 study of Postoperative Pain, has completed, sponsored by Heron Therapeutics.

COMPLETED
Registry status
Phase 2
Development phase
463 participants
Enrollment target
3
Study locations

Study Summary

A Phase 2, Randomized, Pilot Study to Investigate the Safety, Efficacy, Pharmacokinetics and Bioavailability of HTX-011, HTX-002, or HTX-009 Administered Via Injection and/or Topical Application Following Unilateral Open Inguinal Herniorrhaphy

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG HTX-011
  • DRUG HTX-002
  • DRUG Bupivacaine HCI (Marcaine)
  • DRUG HTX-011A

Study Locations (3)

Texas

  • - Houston
  • - Houston

California

  • - Anaheim

Trial Details

FieldValue
Enrollment Target 463 participants
Start Date 2015-07
Est. Completion 2017-04
Phase Phase 2

Sponsor

Heron Therapeutics

23 total trials

What the Registry Record Tells You About NCT02504580

The ClinicalTrials.gov registry entry for NCT02504580 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 463 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 224-participant average among 63 other Postoperative Pain trials with a reported enrollment target (107% higher). The listed sponsor is Heron Therapeutics, which has 23 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Postoperative Pain appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.

NCT02504580 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Texas, California.

Frequently Asked Questions

What is clinical trial NCT02504580 about?

NCT02504580 is a clinical study titled "Pilot Herniorrhaphy Study for Postoperative Analgesia". A Phase 2, Randomized, Pilot Study to Investigate the Safety, Efficacy, Pharmacokinetics and Bioavailability of HTX-011, HTX-002, or HTX-009 Administered Via Injection and/or Topical Application Following Unilateral Open Inguinal Herniorrhaphy

What is the current status of trial NCT02504580?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 463 participants. The study started on 2015-07. Estimated completion is 2017-04.

What conditions does trial NCT02504580 study?

This clinical trial studies the following conditions: Postoperative Pain.

What interventions are being tested in trial NCT02504580?

The interventions under investigation include: Placebo (DRUG), HTX-011 (DRUG), HTX-002 (DRUG), Bupivacaine HCI (Marcaine) (DRUG), HTX-011A (DRUG).

Who is sponsoring clinical trial NCT02504580?

This trial is sponsored by Heron Therapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02504580 being conducted?

This trial has 3 study locations across California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Postoperative Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.